Pfizer Stock Dips 40% but Hides a $43B Oncology Bet
Pfizer’s stock is down 40%, but its $43B Seagen acquisition and vast drug pipeline reveal hidden growth potential.
May 3, 20261 min read0 reactions0 comments
Tag archive
Pfizer’s stock is down 40%, but its $43B Seagen acquisition and vast drug pipeline reveal hidden growth potential.